Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance.

Current Opinion in Pharmacology
Evan C Ray

Abstract

Robust clinical data indicate that inhibitors of the sodium/glucose cotransporter 2 (SGLT2) dramatically improve clinical outcomes in diabetes, especially heart failure and progression of kidney disease. Factors that may contribute to these findings include: 1) improved glycemic control, 2) diuresis and reduced extracellular fluid volume, 3) reduced serum uric acid levels, 3) direct myocardial effects, 4) reduction in proteinuria and preservation of kidney function, and 5) correction of diabetic magnesium deficiency. Understanding the mechanisms by which SGLT2 inhibitors improve cardiovascular outcomes has the potential to improve clinical management not only of diabetes, but also of other cardiovascular disorders such as heart failure and chronic kidney disease.

References

Mar 1, 1972·The American Journal of the Medical Sciences·M C LimaO L Ramos
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Phuong-Chi T PhamPhuong-Thu T Pham
Feb 6, 2008·Cardiovascular Drugs and Therapy·Terje S Larsen, Ellen Aasum
Feb 19, 2008·International Journal of Cardiology·O B Stepura, A I Martynow
Aug 6, 2009·Diabetologia·UNKNOWN Control GroupM Woodward
Apr 28, 2011·Current Opinion in Endocrinology, Diabetes, and Obesity·Matthew C Riddle
Mar 14, 2012·Clinical Science·Anke L LamerisJoost G J Hoenderop
Aug 13, 2013·European Journal of Heart Failure·He HuangJi Wang
Jan 28, 2014·The Journal of Clinical Investigation·Ele FerranniniHans-Juergen Woerle
Apr 25, 2015·Advances in Chronic Kidney Disease·Evan C RayThomas R Kleyman
May 1, 2015·American Journal of Hypertension·Peng ChenDao Wen Wang
Aug 27, 2015·Nefrología : publicación oficial de la Sociedad Española Nefrologia·José Antonio Gimeno-OrnaBlanca García-García
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
May 26, 2016·European Journal of Epidemiology·Setor K KunutsorJari A Laukkanen
Jun 15, 2016·The New England Journal of Medicine·Christoph WannerUNKNOWN EMPA-REG OUTCOME Investigators
May 21, 2017·International Journal of Cardiology·Alessandra Di FrancoEdoardo Mannucci
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Apr 18, 2018·European Journal of Epidemiology·Sasiwarang Goya WannametheePeter H Whincup
May 26, 2018·Advances in Chronic Kidney Disease·Kamonwan Tangvoraphonkchai, Andrew Davenport
Nov 13, 2018·The New England Journal of Medicine·Stephen D WiviottUNKNOWN DECLARE–TIMI 58 Investigators
Nov 20, 2018·KI Reports·Evan C RayThomas R Kleyman
Feb 15, 2019·Diabetes, Obesity & Metabolism·Clifford J Bailey
Mar 9, 2019·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Steef KurstjensJeroen H F de Baaij
Apr 17, 2019·The New England Journal of Medicine·Vlado PerkovicUNKNOWN CREDENCE Trial Investigators
Jul 7, 2019·International Journal of Molecular Sciences·Álvaro García-RoperoJuan J Badimon
Aug 11, 2019·Advances in Experimental Medicine and Biology·Dan Liu, Lin-Li Lv
Sep 20, 2019·The New England Journal of Medicine·John J V McMurrayUNKNOWN DAPA-HF Trial Committees and Investigators
Nov 20, 2019·The American Journal of Cardiology·Scott C Thomson, Volker Vallon
Mar 21, 2020·Biochimica Et Biophysica Acta. Molecular Basis of Disease·Ioanna AndreadouCoert J Zuurbier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Related Papers

International Journal of Nephrology and Renovascular Disease
George Vasquez-Rios, Girish N Nadkarni
Cardiovascular & Hematological Disorders Drug Targets
Konstantinos StavropoulosMichael Doumas
© 2021 Meta ULC. All rights reserved